REF has received consulting fees from Decipher Biosciences, Eisai, Seagen/Pfizer, and participated in advisory boards for Telix. BFK received research funding (to Duke) from Janssen Scientific Affairs for this work. She also has served on advisory boards for Blue Earth Diagnostics, Myovant, and Merck, and is a member of the board of directors for Rythera Therapeutics. KEH: Research Funding (to my institution from): Varian Medical Systems, Rising Tide Foundation, Janssen Scientific Affairs. SH: Member of DSMB for Aveo, BMS, J&J, Sanofi. LEH: none. MA: none. DJG has research support (to Duke University) from Acerta, Astellas, BMS, Bayer, Calithera, Exelixis, Janssen, Myovant, Pfizer, Novartis, and Sanofi Aventis, and consulting income from Vizuri Health Sciences, UroToday, Sanofi, Pfizer, Nektar, Myovant, Modra, Merck, Ipsen, Flatiron, Exelixis, Capio, EMD Serono, BMS, Bayer, AstraZeneca, and Astellas. TZ has received research funding (to Duke) from Pfizer, Janssen, Acerta, AbbVie, Novartis, Merrimack, OmniSeq, PGDx, Merck, Mirati, Astellas, and Regeneron; consulting and speaking income from Genentech Roche, Exelixis, Genomic Health, and Sanofi Aventis; has received consulting income from AstraZeneca, Bayer, Pfizer, Foundation Medicine, Janssen, Amgen, MJH Associates, Merck, BMS, Pharmacyclics, and Seattle Genetics. WRB: none. WRL: none. MRH has research funding (to Duke University) from Argos, Bayer, BMS, Exelixis, Pfizer, Merck, and Seattle Genetics and has received consulting and speaking income from BMS, Genentech Roche, Exelixis, and Janssen. PGC receives institutional funding support from Janssen. AJA: Research support (to Duke) from the NIH/NCI, PCF/Movember, DOD, Astellas, Pfizer, Bayer, Janssen, Dendreon, BMS, AstraZeneca, Merck, Forma, Celgene, Amgen, Novartis. Consulting or advising relationships with Astellas, Epic Sciences, Pfizer, Bayer, Janssen, Dendreon, BMS, AstraZeneca, Merck, Forma, Celgene, Clovis, Exact Sciences, Myovant, Exelixis, GoodRx, Novartis.